No segment of the population has remained unaffected by COVID-19. Several social and economic measures have been undertaken to address the emergency and reduce the impact of the crisis, especially on the most vulnerable population. Transplant patients are one such compromised population in which two dosages of the vaccine have shown suboptimal immunogenicity, therefore, requiring urgent intervention.
According to a study published in the journal New England Journal of Medicine, scientists at the UHN have conducted a randomized, double-blind placebo-controlled trial in transplants patients to measure the effectiveness of a third booster dose against COVID-19. Study design Inclusion criteria: o 120 transplants patients o No COVID-19 history o Completed two dosages of COVID-19 Vaccine Half of the population received the third dose at the mark of 2 months from the second dose, and…
